Cempra, Inc.
Investor Relations Department
6340 Quadrangle Drive, Suite 100
Chapel Hill, NC 27517
United States

Visit IR website
Sign-up for email alerts

NASDAQ: CEMP [1]		
Last Trade:		6.88
Trade Time:		4:00 PM ET May 23, 2013
Change:	0.03	(0.438%)
Day Range		6.67 - 6.90
52-Week Range		5.26 - 9.56
Volume		39,700
Market Cap. ($M)		171.340
Shares Out (M)		24.904

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Two lead antibacterial products, both in the treatment of infectious diseases, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.... (more)

Stock Performance

Press Releases [View all]

May 20, 2013
Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)

May 13, 2013
Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan

Apr 26, 2013
Cempra to Present Data on Solithromycin's (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID

Apr 25, 2013
Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results

Apr 24, 2013
Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Third Quarter Financial Results

Mar 7, 2013
Annual Report (10-K)

Apr 15, 2013
Definitive Proxy Statement

Apr 25, 2013
Quarterly Report (10-Q)

Nov 8, 2012
Quarterly Report (10-Q)

Aug 8, 2012
Quarterly Report (10-Q)

NASDAQ OMX